BerGenBio ASA reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was NOK 0.389 million compared to NOK 0.774 million a year ago. Net loss was NOK 302.12 million compared to NOK 309.36 million a year ago.

Basic loss per share from continuing operations was NOK 3.41 compared to NOK 3.52 a year ago.